For men enrolled in active surveillance, pre-biopsy biparametric magnetic resonance imaging significantly reduces the risk of reclassification and disease progression after 1 year. (4th May 2021)

• Record Type: Journal Article
• Authors: Kortenbach, Karen-Cecilie; Boesen, Lars; Løgager, Vibeke; Thomsen, Henrik S.
• Is Part Of: Scandinavian journal of urology. Volume 55:Number 3(2021)
• Page Start: 215
• Page End: 220
• Publication Date: 2021-05-04
• Subjects: Active surveillance -- biparametric magnetic resonance imaging -- multiparametric magnetic resonance imaging -- prostate cancer; Urology -- Periodicals; 616.6
• DOI: 10.1080/21681805.2021.1897158
• Languages: English
• ISSNs: 2168-1805

Abstract

Abstract: Aims: To assess the level of disease progression at confirmatory staging biopsies after 1 year of active surveillance (AS) and compare the detection rate of significant prostate cancers (PCas) in patients who underwent pre-biopsy biparametric magnetic resonance imaging (bpMRI) before the first set of diagnostic transrectal ultrasonography-guided biopsies (TRUS-bx) with the detection rate in patients who did not undergo pre-biopsy bpMRI. Materials and methods: Comparison of two patient groups enrolled in AS. Patients in Group A ( n = 127) underwent pre-biopsy bpMRI followed by TRUS-bx ± targeted biopsies. Patients in Group B ( n = 127) were enrolled in AS based on biopsy results from TRUS-bx only. Results: Overall, 6% of the patients in Group A and 20% of the patients in Group B had an upgrade in Gleason grade from insignificant to significant PCa at confirmatory staging biopsies (odds ratio [OR], 3.5; p = .002; 95% confidence interval [CI], 1.6–7.9). Conclusions: Patients who underwent pre-biopsy bpMRI before the first set of diagnostic biopsies had a reduced risk of reclassification and disease progression after 1 year of AS. Thus, pre-biopsy bpMRI improves the selection of men who should be enrolled in AS.